The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Mesitskaia D.F.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Nikitina Yu.M.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Aksenova M.G.

A.N. Sysin Research Institute of Human Ecology and Environmental Hygiene of Russian Ministry of Health, Moscow, Russia

Dobrovolsky A.V.

Chair of Preventive and Emergency Cardiology, Research Center of Mental Health RAS, Moscow, Russia

Lomakin O.V.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii, Moskva

Chernyi O.V.

ZAO «LAGIS» Gene Engineering Systems Laboratory, Moscow, Russia

Positive effect of low-activity thromboxane A synthase 1 gene on prognosis in coronary heart disease

Authors:

Kopylov F.Iu., Mesitskaia D.F., Nikitina Yu.M., Aksenova M.G., Dobrovolsky A.V., Lomakin O.V., Chernyi O.V.

More about the authors

Journal: Therapeutic Archive. 2015;87(3): 59‑65

DOI: 10.17116/terarkh201587359-65

Read: 2377 times

Download PDF (RU)
Contact the author
Table of contents

POSITIVE EFFECT OF LOW-ACTIVITY THROMBOXANE A SYNTHASE 1 GENE ON PROGNOSIS IN CORONARY HEART DISEASE
POSITIVE EFFECT OF LOW-ACTIVITY THROMBOXANE A SYNTHASE 1 GENE ON PROGNOSIS IN CORONARY HEART DISEASE

To cite this article:

Kopylov FIu, Mesitskaia DF, Nikitina YuM, Aksenova MG, Dobrovolsky AV, Lomakin OV, Chernyi OV. Positive effect of low-activity thromboxane A synthase 1 gene on prognosis in coronary heart disease. Therapeutic Archive. 2015;87(3):59‑65. (In Russ.)
https://doi.org/10.17116/terarkh201587359-65

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Exploring the capa­bility of the cardiovascular risk evaluation using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(3):53-59
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Two years expe­rience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220
The place of non-high-density lipo­protein cholesterol and triglycerides in the asse­ssment of cardiovascular risk: Reso­lution of the Panel of Expe­rts. Russian Journal of Preventive Medi­cine. 2025;(4):7-15
Creating an index reflexing cardiovascular risk using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(4):82-88
QRISK-3 cardiovascular risk asse­ssment algo­rithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69
The Webiomed.DHRA deci­sion-making support system for medi­cal examinations in the Russian Fede­ration: a cost-effectiveness analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):61-73
Abstract:

Aim. To analyze the influence of pharmacogenetic factors on the risk of clopidogrel resistance and cardiovascular events during 18-months follow-up.  Subjects and methods. Two hundred and fifty patients taking clopidogrel were examined. Platelet function was determined by optical aggregometry. Thromboxane A synthase 1 (TBS1) gene polymorphism was investigated in all the patients. The impact of TBS1 gene polymorphism on the risk of clopidogrel resistance and cardiovascular events was analyzed during 18 months of follow-up. Results. The carriage of TBS1 gene polymorphism AA was shown to affect the risk of clopidogrel resistance. Cardiovascular complications significantly less frequently occurred in TBS1 gene polymorphism AA carriers during 18 months. Conclusion. The carriage of a slow AA allele of the TBS1 gene is suggested to be a clinically significant protective factor in the secondary prevention of coronary heart disease

Keywords:

clopidogrel resistance
thromboxane synthase gene
cardiovascular risk

Authors:

Kopylov F.Iu.

Pervyĭ MGMU im. I.M. Sechenova, kafedra profilakticheskoĭ i neotlozhnoĭ kardiologii FPPOV, Moskva

Mesitskaia D.F.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Nikitina Yu.M.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Roszdrava, Moskva

Aksenova M.G.

A.N. Sysin Research Institute of Human Ecology and Environmental Hygiene of Russian Ministry of Health, Moscow, Russia

Dobrovolsky A.V.

Chair of Preventive and Emergency Cardiology, Research Center of Mental Health RAS, Moscow, Russia

Lomakin O.V.

GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii, Moskva

Chernyi O.V.

ZAO «LAGIS» Gene Engineering Systems Laboratory, Moscow, Russia

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.